Loading clinical trials...
Loading clinical trials...
Randomized, Multi-center, Double-blind, Placebo-controlled, Group-comparison Study to Investigate Safety, Tolerability and Pharmacodynamics of BAY2253651 After Administration of a Single Nasal Dose in 60 Subjects With Obstructive Sleep Apnea and Open Exploratory Evaluation of Safety and Local Tolerability of Repeated Doses in Patients
Conditions
Interventions
BAY2253651
Placebo
Locations
2
Switzerland
University Hospital Zürich
Zurich, Switzerland
Oxford University Hospitals
Oxford, United Kingdom
Start Date
August 13, 2018
Primary Completion Date
May 23, 2019
Completion Date
September 2, 2019
Last Updated
December 11, 2020
NCT07446634
NCT07191314
NCT05497180
NCT04712656
NCT03860233
NCT04399200
Lead Sponsor
Bayer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions